Issue/Argument: Asia has rising cases of hepatitisB/C. Alcohol/Food-habits cause high prevalence in rural/tribal areas. Lack of monitoring/follow-up complicates management. vaccines emerge as hope. Clinical-trials of vaccines debated-issue. Design of hepatitis-vaccine-trials in developing-countries complex ethical-issue. We focus on controversies identified in international/regional/local CME/pharma programs as vulnerability of volunteers to exploitation by foreign/local research-groups/funding-agencies. Critical task is protect interests of vaccine-subjects in face of substantial-risks. Determine if hepatitis-Vaccine-volunteers will have access to treatment during trial. Access to Vaccine-trial-outcome. Interaction with seniors 19 th APASL-Congress from developed-countries will give voice to such burning-issues. Methodology: Researchers/pharmaceuticals/Govt-policy planners need to develop forum to solve these problems. NGO's can play pivotal role. Obligation on part of researchers to create mechanisms to offset anticipated risks of participation in controversial, Risky vaccine-development. Conclusion: counselling/right to withdraw from trial be made basic guideline. Apart from monetary aspects unsuspected adverse reactions/deaths be properly evaluated/monitored. Researchers need to evolve policy-guidelines to overcome barriers as variation in interpretation of essential ethical ideas, legal-system-differences, educational/economic-status. Need to develop common consensus between research-community/pharma sector to reduce suffering of hepatitis-affected patients community.